Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: Experience at the Medical University of Vienna

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2379-2382

  Bojic, Marija ^a,b   Pluschnig, Ursula ^a,b   Zacherl, Johannes ^a,b   Thallinger, Christiane M R ^a,b   Ba Ssalamah, Ahmed ^b   Maresch, Judith ^b   Datler, Philip ^a,b   Schoppmann, Sebastian F ^a,b   Hejna, Michael ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

5 fluorouracil; Cisplatin; DCF; Docetaxel; G CSF; Gastric cancer; Gastroesophageal junction adenocarcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUTH INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; POLYNEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS;

EID: 79960454194     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wohrer SS, Raderer M and Hejna M: Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15: 1585-1595, 2004. (Pubitemid 39567288)
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006. (Pubitemid 46630593)
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H and Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997. (Pubitemid 27112884)
4. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
5. Scheithauer W, Kornek GV, Zeh B, Raderer M and Depisch D: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial. Second Int Conf Biol Prev Treat GI, Malign, Köln, 1995; 10: 68 (Abstr 129), 1995.
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
7. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L and Van Cutsem E: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3210-3216, 2007. (Pubitemid 47325603)
8. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C and Van Cutsem E: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3205-3209, 2007.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006. (Pubitemid 46631401)
10. Cascinu S, Graziano F, Barni S, Labianca R, Cornelia G, Casaretti R, Frontini L, Catalano V, Baldelli AM and Catalano G: A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 84: 470-474, 2001. (Pubitemid 32215871)
11. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC and Zielinski C: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47: 8-32, 2011.
12. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C and Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18: 1673-1679, 2007. (Pubitemid 47506254)
13. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J and Phan A: Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116: 1446-1453, 2010.
14. Hainsworth JD, Burris HA 3rd,Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB and Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19: 3500-3505, 2001. (Pubitemid 32730087)
15. Hainsworth JD and Greco FA: The role of weekly docetaxel in the treatment of advanced non-small cell lung cancer. Clinical Lung Cancer 3(Suppl 2): S17-22, 2002.
16. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL and Baselga J: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15: 1358-1365, 2004. (Pubitemid 39295024)
17. Cannistra SA: Phase II trials in journal of clinical oncology. J Clin Oncol 27: 3073-3076, 2009.
18. Kola I and Landis J: Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc 3: 711-715, 2004.
19. Kang Y, Othsu A and Van Cutsem E: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. J Clin Oncol 28: S18 (Abstr 4007), 2010.
20. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J and Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.